Storefriendly Introduces New Self-Service Storage System & IoT-Driven Smart Management — Enhanced Facilities to Meet Evolving Customer Needs
Award-Winning Innovation: Cutting-edge Self-Service Storage System
Storefriendly's innovative self-service storage solution earned the 2025 SSAA 'I&T Award (Hong Kong)', underscoring the Group's relentless pursuit of innovation and its role in setting new standards for the industry. Embracing the digital era, Storefriendly has pioneered the integration of the O2O (Online-to-Offline) model to streamline the storage rental process. Customers can now select branches and unit sizes, complete payments, and confirm bookings online, all from their mobile devices or computers. Upon confirmation, a QR code is issued for seamless access to the selected branch, enabling a swift and user-friendly move-in process.
ADVERTISEMENT
24/7 Security and IoT Monitoring for Enhanced Safety
Storefriendly's physical locations are equipped with 24/7 security surveillance and automated environmental monitoring, powered by Internet of Things (IoT) technology. This system detects anomalies such as power surges or water leakage in real time, ensuring rapid response and optimal storage conditions. Coupled with a 24-hour customer support hotline, these features offer customers peace of mind when using the self-service storage units.
Hybrid AI + Human Customer Service for Faster & More Personalized Support
Customer service is another cornerstone of Storefriendly's development strategy. After years of listening to customer feedback, the Group identified a need for faster and more in-depth support. By incorporating a smart AI-driven customer service system, Storefriendly now offers 24-hour assistance for basic inquiries and facility tour bookings. At the same time, the Group remains committed to providing personalized support through human agents during service hours, ensuring a premium and empathetic customer experience.
Full-Building Storage Tower Ecosystem Promoting Sustainability
In addition to offering comprehensive storage services, Storefriendly Tower locations, including the Lai Chi Kok branch, are equipped with solar systems and EV charging stations, reinforcing the Group's commitment to environmental sustainability. These green initiatives have earned the Group the 'ESG Award (Hong Kong)', recognizing its leadership in sustainable development within the storage industry.
Premium, Club-Level Facilities Unlock New Possibilities for Storage
As Hong Kong's first full-building self storage ecosystem, Storefriendly Tower provides club-class storage experiences with added-value amenities that enrich the customer journey. These include but are not limited to:
Free on-site parking with complimentary EV charging
Bike repair station for cycling enthusiasts renting bike units
Tool stations on traditional storage floors to facilitate packing and transport
Dedicated workspaces for customers to handle personal tasks etc.
Specialized Storage: Wine Storage & Safety Box
Beyond conventional storage, Storefriendly is expanding into specialized and boutique storage solutions, such as climate-controlled wine cellars and on-demand safety boxes. The wine storage units are equipped with temperature and humidity control systems to preserve wine quality, while the smart safes offer high-security storage for valuables with real-time monitoring and secure access, meeting the diverse needs of modern customers.
Hashtag: #StoreFriendlyTower
The issuer is solely responsible for the content of this announcement.
About Storefriendly Self Storage Group
Founded in 2002, Storefriendly Self Storage Group is one of Asia's leading self storage brands, operating over 90 branches and 40,000 storage units across Hong Kong, Macau, Singapore, and Taiwan. More than half of its branches are self-owned properties, strategically located with 24-hour smart access systems and robust security infrastructure. The Group is committed to providing safe and flexible storage solutions for both personal and business clients.
Storefriendly continues to invest in technology, including AI customer service, wine cellars, and smart safes, to enhance service quality and deliver an exceptional storage experience.
Visit Storefriendly: https://storefriendlytower.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Channel Post MEA
5 hours ago
- Channel Post MEA
Group-IB Launches Fraud Matrix 2.0 For Fraud Detection And Prevention
Group-IB has announced the launch of Fraud Matrix 2.0 – a state-of-the-art analytics tool designed to help organisations detect, respond to, and prevent fraud with greater accuracy and agility. Inspired by the MITRE ATT&CK framework, Fraud Matrix is a unique comprehensive framework developed by Group-IB, designed to describe the actions and behaviours employed by fraudsters across a wide range of illicit activities. It serves as a strategic tool to deepen understanding of fraudulent behavior and enhance prevention and detection of threats. Fraud Matrix 2.0, is an upgraded and improved version of the framework that further bridges the gap between cybersecurity and fraud prevention, offering a pioneering, unified perspective for tackling modern fraud threats. The next-generation Fraud Matrix boasts a suite of enhancements designed to give organisations deeper insight, faster response, and stronger control over fraud threats. Key updates include: Threat actor profiles – Detailed insights into fraudster behaviours, motives, and tactics for more targeted threat identification. Fraud software intelligence – A breakdown of tools and malware used in fraud schemes across industries. Campaign intelligence – Real-time insights into evolving fraud and scam campaigns to support faster disruption. New mitigations and detections – Updated techniques to strengthen defences and improve detection accuracy. Self-assessment wizard – A quick way for organizations to evaluate their control coverage and identify gaps. Cross-industry fraud taxonomy – A standardised framework to classify and communicate fraud types across sectors. Since its initial public launch in 2024, Fraud Matrix has seen adoption by over 80 organisations across 30+ countries, spanning industries from banking and telecom to retail and government. The framework has already delivered a measurable impact: Detection coverage increased from 55% to 91%, enabling organizations to identify and address a broader range of fraud techniques. Response times improved by 85.6%, helping teams act faster and reduce the impact of fraud incidents. 'Fraud is evolving rapidly, and traditional defences are no longer enough. With the next generation of the Fraud Matrix Framework, we're giving organizations a smarter, more structured way to understand and counter fraud threats. It empowers fraud teams to act faster, cover more ground, and stay ahead of increasingly complex schemes.' The upgraded Fraud Matrix also supports industry-specific fraud landscape analysis, helping organizations identify blind spots and prioritize defences according to the most relevant threats in their region or sector. Group-IB continues to collaborate with global cybersecurity framework communities while also exploring future enhancements that will continue to advance the framework through shared intelligence, emerging TTPs, and real-world detection strategies. As the Fraud Matrix evolves, Group-IB remains at the forefront of cybersecurity and anti-fraud innovation.
Zawya
19 hours ago
- Zawya
Savola Group's profits shrink 39% in H1-25; higher revenues reported
The net profit of Savola Group amounted to SAR 294.86 million in the first half (H1) of 2025, down 39.09% year-on-year (YoY) from SAR 484.10 million, according to the financial results. Revenues soared by 11.25% to SAR 13.65 billion as of 30 June 2025 from SAR 12.27 billion in H1-24, while the earnings per share (EPS) increased to SAR 0.99 from SAR 0.53. Results for Q2-25 In the second quarter (Q2) of 2025, the company logged net profits valued at SAR 105.70 million, marking an annual drop of 21.92% from SAR 135.39 million. The revenues grew by 18.16% YoY to SAR 6.06 billion in April-June 2025 from SAR 5.13 billion. Quarterly, the Q2-25 profits retreated by 44.12% from SAR 189.16 million in January-March 2025, while the revenues dropped by 20.21% from SAR 7.59 billion. All Rights Reserved - Mubasher Info © 2005 - 2025 Provided by SyndiGate Media Inc. (
Web Release
20 hours ago
- Web Release
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Hikma Pharmaceuticals PLC and its subsidiaries ('Hikma' or 'Group'), the multinational pharmaceutical company, today reports its interim results for the six months ended 30 June 2025. The Group reported revenue growth of 6% (5% in constant currency) to $1.658 billion (compared to $1.569 billion in H1 2024). We continued to implement our strategic priorities in the first half of 2025. Our MENA business had a strong first half, building market share across the portfolio and we remained the second largest pharmaceutical company by sales[1], with a growing portfolio and reach in MENA. We also maintained our position as a top-three US provider of generic sterile injectables by volume[2] and a key supplier of non-injectable generic medicines. In Europe, we are the sixth largest supplier of injectables by sales[3] thanks to our expansion in France, Spain and the UK. We also strengthened our pipeline through strategic partnerships and agreements by signing seven partnerships across all three businesses, including an exclusive licensing agreement with pharmaand GmbH (pharma&) to commercialise rucaparib, an innovative oral oncology therapy, across MENA. We continue to expect Group revenue to grow in the range of 4% to 6% for the full year, reflecting good growth in the Branded and Injectables businesses, offset by a slight decline in Hikma Rx, (the Generics business in the US). Riad Mishlawi, Chief Executive Officer of Hikma, said: 'In the first half of 2025, the strategic changes and renewed focus we put in place have started to deliver tangible results. We achieved strong revenue growth and built solid momentum across the business. While core operating profit was lower due to strong comparator in 2024 and a change in product mix, we expect a return to growth in the second half and are pleased to reiterate our full-year 2025 guidance for the Group. Demand across our portfolio remains robust, we are successfully launching new products, strengthening our manufacturing capabilities, and securing key strategic are also making significant strides in advancing our pipeline and increasing our investment in R&D. With this foundation, we are well-positioned for the future and I look forward to sharing more updates on our continued growth.' Our Injectables business, which manufactures and supplies generic injectable medicines to hospitals across North America, Europe and MENA, delivered 12% revenue growth in the first half, with profit impacted by a change in product mix and the strong appreciation of the Euro. In North America, we are benefitting from recently launched products as well as the contribution from the Xellia portfolio, which we acquired in September 2024. During the first half, we received FDA approval for the biosimilar Ustekinumab, and for our reformulated vancomycin ready-to-use bag, TYZAVANTM which we will be launched in the second half. Our MENA business had a strong first half, building market share across the portfolio. We had a good performance from our oncology, biotechnology and anti-infective portfolios as well as new launches, including our first diagnostic product from our partnership with Guardant Health. In Europe, we are seeing strong demand for our own products, particularly in recently entered markets such as France, driven by an expanding portfolio and market shortage dynamics. During H1 2025, we launched 33 products and submitted 21 filings to regulatory authorities across all markets. We expect Injectables revenue to grow in the range of 7% to 9%. Our Branded business, which supplies branded generics and in-licensed patented products across the MENA region, grew 4%, reflecting increased market share across the region. Chronic therapy areas remain a key driver of our expansion, with treatments for diabetes, respiratory illness and multiple sclerosis all contributing to growth in the first half. We also remain a leader in oral oncology in the region, with a particularly good contribution from recently launched products, including the targeted breast cancer therapy, palbociclib, sold under our brand name Papillio, a first generic of this important medicine in Algeria. We have a significant and expanding manufacturing presence in the region, where localisation is key to our strategy, and during the first half of 2025 we have continued to make operational enhancements, including facility expansions, automation and rolling out inspection-readiness programmes, which will collectively improve efficiencies and enhance our quality levels. During H1 2025, we launched 14 products and submitted 36 filings to regulatory authorities. We now expect Branded revenue to grow in the range of 6% to 7% on both a constant currency and reported basis. Hikma Rx, which supplies oral and other non?injectable generic and specialty products to the US retail market, delivered a good first half performance against a heavily H1-weighted 2024 result. Hikma Rx revenue is down 1% as expected with differentiated portfolio performing well. We continued increasing investment to support growth and R&D, while the successful integration of Xellia strengthened Injectables and Hikma Rx. Our differentiated portfolio is performing well with strong volume growth, especially for our inhalation products, which is partially offsetting expected levels of price erosion. We have also maintained our strong position in the sodium oxybate market. We continue to leverage our state-of-the-art facility production in Columbus, Ohio for contract manufacturing for a range of customers, and preparations at the site are ongoing for our previously announced contract with a large global pharmaceutical company. We expect Hikma Rx revenue to be broadly flat vs 2024. [1] Based on internal analysis by using data from the following source: IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE, for the period: calendar year 2024, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved [2] IQVIA MAT June 2025, generic injectable volumes by eaches, excluding branded generics and Becton Dickinson [3] IQVIA Injectable generic products, Hospital + Germany Retail, 2024 USD sales
